Live
Glenmark Pharma has got the US health regulator’s approval for its investigational new drug application to initiate phase one study of GBR 1342, a humanised monoclonal antibody to treat multiple myeloma.
This is the second investigational new drug of the company from its immuno-oncology portfolio to enter clinical trials.
Glenamrk has said in a BSE filing that “GBR 1342 is designed to activate the patient’s immune system by redirecting immune cells towards tumour tissue, which may lead to targeted destruction of tumours. It is based on Glenmark’s proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform.”
